GlassScriptPhysician profile
Sisay Michael Abraham
NPI 1184088312
$1,023.60
in general payments reported to CMS, 2019-2025
12 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.76 · 2022: $194 · 2023: $379 · 2024: $315 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $798.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $382.41 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $282.45 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $105.73 | 2023-2024 | Mounjaro, Zepbound, Trulicity |
| Astellas Pharma US INC | $66.94 | 2024-2025 | Veozah |
| Abbott Laboratories | $33.48 | 2021-2022 | |
| Glaxosmithkline, LLC. | $33.00 | 2023-2024 | Arexvy, Shingrix, Bexsero |
| Sumitomo Pharma America, INC. | $30.64 | 2023-2024 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $20.59 | 2022 | |
| Amgen INC. | $20.04 | 2023 | Evenity, Prolia |
| Medtronic, INC. | $16.90 | 2023 | Intellis Adaptivestim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.89 | 2023 | |
| Almatica Pharma LLC | $14.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sisay Michael Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.